Laurie Zografos, BS

RTI Health Solutions

Disclosure(s): Viiv: ViiV provided funding to RTI for the development of the study materials, the conduct of the study, and analysis & interpretation of study results.

Poster(s):

• 1288 - US Healthcare Provider Perspectives on the initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND)
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET